Engimata
Engimata is an early stage biopharma company located in the San Francisco Bay Area, specializing in platform nano lipid particle technology for vaccine development. Their mission is to improve efficacy and stability of vaccines against infectious diseases to extend life expectancy and save lives. They develop patented lipid-based vaccine adjuvants and lipid nanoparticles (LNPs) for R&D, enabling the creation of more effective and stable vaccines across a wide temperature range (-40°C to 40°C). The company actively participates in scientific conferences, presents research on COVID-19 vaccines, and holds patents related to vaccine technology. Engimata collaborates with institutions like MIT and is recognized as an economic driver in Pleasanton, CA.
Industries
Nr. of Employees
small (1-50)
Engimata
Pleasanton, California, United States, North America
Products
Lipid nanoparticle-based vaccine adjuvant platform
A lipid-based particulate adjuvant and delivery platform formulated with natural lipids and approved excipients to enhance immune response, improve antigen stability, and enable thermostable vaccine formats.
Lipid nanoparticle-based vaccine adjuvant platform
A lipid-based particulate adjuvant and delivery platform formulated with natural lipids and approved excipients to enhance immune response, improve antigen stability, and enable thermostable vaccine formats.
Services
Provision of lipid nanoparticle and adjuvant formulations for vaccine R&D
Supply of liposome or lipid nanoparticle formulations and adjuvant delivery systems for use in vaccine research and development; formulations can be customized for different antigens.
Provision of lipid nanoparticle and adjuvant formulations for vaccine R&D
Supply of liposome or lipid nanoparticle formulations and adjuvant delivery systems for use in vaccine research and development; formulations can be customized for different antigens.
Expertise Areas
- Vaccine adjuvant development
- Lipid nanoparticle and liposome formulation
- Thermostable vaccine formulation
- Lyophilization / freeze-drying for biologics
Key Technologies
- Liposomal nanoparticles
- Lipid nanoparticles (LNP)
- Lyophilization / freeze-drying
- Thermal analysis